# US 2018/0021423 A1 · Methods and compositions for attenuated chlamydia as vaccine and vector

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021423 A1
- Document ID: US20180021423A1
- Status: Published application
- Kind: A1
- Application number: 15/551,829
- Filed: 2016-02-19
- Published: 2018-01-25
- Earliest claimed: 2015-02-20
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Guangming Zhong
- Web page: https://patentgrep.com/patent/US20180021423A1

## CPC

- A61K 39/118: Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
- C07K 14/295: from Chlamydiales (O)
- C12N 1/36: Adaptation or attenuation of cells
- A61K 2039/522: {avirulent or attenuated}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides Chlamydia organisms and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for use as vectors.

## Claims

### Claim 1

An isolated Chlamydia trachomatis cell comprising
a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:1; and
b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:2,
wherein said Chlamydia trachomatis cell has a phenotype due to said substitution of (a) and said mutation and/or substitution of (b) of attenuated pathogenicity.

### Claim 2 (depends on 1)

The isolated Chlamydia trachomatis cell of claim 1, wherein the substitution in open reading frame CT849 is Q117E.

### Claim 3 (depends on 1)

The isolated Chlamydia trachomatis cell of claim 1, wherein the substitution in open reading frame CT389 is G322R.

### Claim 4 (depends on 1)

The isolated Chlamydia trachomatis cell of claim 1, further comprising a mutation in the open reading frame CT135 selected from the group consisting of:
a) a CT135fs29 mutation;
b) a CT135E88* mutation;
c) a CT125fs145 mutation; and
d) any combination of (a)-(c) above,
wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:3.

### Claim 5 (depends on 1)

The isolated Chlamydia trachomatis cell of any of claim 1, further comprising a heterologous nucleic acid molecule.

### Claim 6 (depends on 1)

A composition comprising the isolated Chlamydia trachomatis cell of claim 1 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 5)

A composition comprising the isolated Chlamydia trachomatis cell of claim 5 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method of treating and/or preventing a disorder associated with or caused by chlamydial infection in a subject, comprising administering to the subject an effective amount of the isolated Chlamydia trachomatis cell of claim 1.

### Claim 9 (depends on 1)

A method of eliciting an immune response to Chlamydia in a subject, comprising administering to the subject an effective amount of the isolated Chlamydia trachomatis cell of claim 1.

### Claim 10 (depends on 1)

A method of reducing the likelihood of infertility due to Chlamydia infection in a subject, comprising administering to the subject an effective amount of the isolated Chlamydia trachomatis cell of claim 1.

### Claim 11 (depends on 1)

A method of reducing the incidence of hydrosalpinx due to Chlamydia infection in a subject, comprising administering to the subject an effective amount of the isolated Chlamydia trachomatis cell of claim 1.

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering an adjuvant to the subject.

### Claim 13 (depends on 5)

A method of delivering a heterologous nucleic acid molecule to a subject, comprising administering to the subject the Chlamydia trachomatis cell of claim 5.

### Claim 14 (depends on 13)

The method of claim 13, wherein the heterologous nucleic acid molecule encodes a therapeutic protein or therapeutic RNA.

### Claim 15 (depends on 13)

The method of claim 13, wherein the Chlamydia trachomatis cell is administered to mucosal tissue of the subject.

### Claim 16 (depends on 13)

The method of claim 13, wherein the Chlamydia trachomatis cell is administered to the gastrointestinal (GI) tract of the subject.

### Claim 17 (depends on 5)

A method of inducing an immune response to an immunogen in a subject, comprising administering to the subject the Chlamydia trachomatis cell of claim 5, wherein the heterologous nucleic acid molecule encodes the immunogen.

### Claim 18 (depends on 17)

The method of claim 17, wherein the immunogen is a human immunodeficiency virus (HIV) protein or immunogenic fragment thereof.

### Claim 19 (depends on 5)

A method of treating a gastrointestinal disorder in a subject, comprising administering to the gastrointestinal tract of the subject the Chlamydia trachomatis cell of claim 5.

### Claim 20

A method of delivering a heterologous nucleic acid molecule to a GI tract of a subject, comprising administering to the GI tract of the subject a Chlamydia trachomatis cell that does not comprise a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of CT849 as provided herein as SEQ ID NO:1; and b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2 and that comprises a heterologous nucleic acid molecule.

### Claim 21

A method of inducing an immune response in the GI tract of a subject, comprising administering to the subject a Chlamydia trachomatis cell comprising a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of CT849 as provided herein as SEQ ID NO:1; and b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2, thereby inducing an immune response to the Chlamydia trachomatis cell in the GI tract of the subject.

### Claim 22

A method of inducing an immune response in the GI tract of a subject, comprising administering to the subject a Chlamydia trachomatis cell that does not comprise a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of CT849 as provided herein as SEQ ID NO:1; and b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2, thereby inducing an immune response to the Chlamydia trachomatis cell in the GI tract of the subject.

### Claim 23

An isolated CT389 polypeptide comprising a G216* nonsense mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2.

### Claim 24 (depends on 23)

A composition comprising the isolated CT389 polypeptide of claim 23 in a pharmaceutically acceptable carrier.

### Claim 25 (depends on 23)

A method of inducing an immune response in a subject, comprising administering to the subject the isolated CT389 polypeptide of claim 23.

### Claim 26 (depends on 23)

A method of treating, ameliorating and/or preventing a disease or disorder due to Chlamydia infection in a subject, comprising administering to the subject the isolated CT389 polypeptide of claim 23.
